| Editor's Choice: Heart Health | Michael J. Barry, MD, vice chair of the U.S. Preventive Services Task Force, gave Cardiovascular Business an overview of the new recommendations. Michael J. Barry, MD, vice chair of the U.S. Preventive Services Task Force, gave Cardiovascular Business an overview of the new recommendations. | | |
| The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen. The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen. | | |
| Metformin appears to improve the impact of chemodynamic therapy, according to a new analysis in Nano Research. Metformin appears to improve the impact of chemodynamic therapy, according to a new analysis in Nano Research. | | |
| “Our results are relevant to clinical practice, supporting the use of the Mediterranean diet in secondary prevention," researchers wrote. “Our results are relevant to clinical practice, supporting the use of the Mediterranean diet in secondary prevention," researchers wrote. | | |
| The American College of Cardiology (ACC), Association of Black Cardiologists, American Heart Association and Society for Cardiovascular Angiography & Interventions are just some of the healthcare organizations supporting the FDA's proposal. The American College of Cardiology (ACC), Association of Black Cardiologists, American Heart Association and Society for Cardiovascular Angiography & Interventions are just some of the healthcare organizations supporting the FDA's proposal. | | |
| A team of researchers used computer science and mathematics to study the "triple whammy" of diuretics, RAS inhibitors and NSAIDs. A team of researchers used computer science and mathematics to study the "triple whammy" of diuretics, RAS inhibitors and NSAIDs. | | |
| The study's authors tracked data from six different randomized controlled trials, including a large study from 2021 that focused on myocardial infarction patients. The study's authors tracked data from six different randomized controlled trials, including a large study from 2021 that focused on myocardial infarction patients. | | |
| The SGLT2 inhibitor is already known as an effective medication for both type 2 diabetes and heart failure. The SGLT2 inhibitor is already known as an effective medication for both type 2 diabetes and heart failure. | | |
| |
|
| ![]() | |
|
